Top Ten most popular articles on Pharmafile.com this week

pharmafile | July 28, 2017 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing biotech, drugs, healthcare, pharma, pharmaceutical, top 10 

It’s Friday, and it’s been a week characterised by a range of promising research results, particularly into HIV and Duchenne muscular dystrophy. But this all fell into shadow; by far, the biggest news this week was the release of AstraZeneca’s long-awaited data from it’s Mystic trial into lung cancer. The company is still reeling from the news, whcih caused more than $10 billion to be wiped from its market value.

Check out the week’s ten most popular articles on Pharmafile.com now!

10. Study contradicts widely held belief on length of antibiotics use

If you’ve ever taken a course of antibiotics then you will be familiar with the piece of advice that is often handed out alongside the prescription – to make sure you complete the full course of the antibiotics. A new study emerged, published in the BMJ has countered this by suggesting that this direction is not based on evidence.

9. Breakthrough gene therapy shows promise in Duchenne muscular dystrophy

New research, led by teams from AFM-Telethon laboratory in Nantes and the University of London, have developed a gene therapy for Duchenne muscular dystrophy (DMD) that has shown significant promise in treating the muscle-wasting disease.

8. Janssen single tablet regimen shows Phase 3 success in HIV

The latest Phase 3 data investigating Janssen’s darunivir in the treatment of human immunodeficiency virus (HIV-1) showed that the drug was effective and safe, Janssen has announced.

7. $1.1 billion swoop for promising Parkinson’s drug developer

Mitsubishi Tanabe Pharma (MTPC) has announced that it has moved to acquire Israeli pharma company, NeuroDerm, in a deal worth $1.1 billion.

6. Over 3% of all drugs in Indian market not up to standard

The Central Drugs Standard Control Organisation (CDSCO) tested drugs to determine whether they were of standard quality but found that 946 of the medicines across 66 companies failed the test.

5. Leo Pharma gets European approval for unique plaque psoriasis drug

The European Commission has announced that it has decided to approve Leo Pharma’s Kyntheum (brodalumab), making it the first and only available therapy to target the IL-17 receptor in the treatment of moderate-to-severe plaque psoriasis in candidates for systemic therapy.

4. Trump throws weight behind pharmaceutical manufacturing

In a press conference at the White House, President Trump, alongside representatives from Corning, MSD and Pfizer, announced that 1,000 jobs would be created in a new pharmaceutical glass packaging initiative.

3. Celgene agrees one of the largest settlements for false claims on record

It has been announced that Celgene has agreed to settle a case after a whistle-blower launched a lawsuit against the company, claiming it had made false claims to improve sales of two drugs.

2. GSK unveil appointment coup for board of directors

GSK continue its appointment spree with a particularly notable staff acquisition, with leading immuno-oncology scientist, Dr Laurie Glimcher, joining its Board of Directors.

1. AZ’s ‘blockbuster’ lung cancer drug fails, Q2 revenue falls

The long-awaited results for AstraZeneca’s Mystic trial have been revealed and, in a shocking setback for the company, it was found that its injectable immunotherapy treatments do not outperform standard chemotherapy.

Related Content

FDA approves IMIDEX’s AI-powered device VisiRad XR

The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …

Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo

On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …

Zumutor’s cancer drug trial cleared by FDA

On 11 August 2023, the biopharmaceutical company Zumutor Biologics announced that the trial of its …

Latest content